DAM
ORMP icon

Draper Asset Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Draper Asset Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,320
Closed -$17.1K – 44
2023
Q1 		$11.6K Sell
5,320
-4,654
-47% -$14.8K 0.01% 29
2022
Q4 		$120K Buy
+9,974
New +$77.5K 0.17% 27

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Draper Asset Management's ORMP Position: Q2 2023 in Review

Draper Asset Management sold out of Oramed Pharmaceuticals (ORMP) in Q2 2023, closing a stake of 5,320 shares — an estimated $17.1K sold.

Draper Asset Management first reported a position in ORMP in Q4 2022 and held it in 2 quarters. The position peaked at $120K in Q4 2022. 50 funds tracked by Wall St. Rank hold ORMP as of Q2 2023.

  • Draper Asset Management reported no remaining Oramed Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Draper Asset Management sold 5,320 Oramed Pharmaceuticals shares in Q2 2023, an estimated $17.1K.
  • Draper Asset Management first reported a position in Oramed Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Draper Asset Management's Oramed Pharmaceuticals position peaked at $120K in Q4 2022.
  • 50 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2023.

Based on Draper Asset Management's 13F filing for Q2 2023, filed 3 Aug 2023.